Obinutuzumab for refractory minimal change disease in obese patients: a case series - Top-Institutions - MDSpire

Obinutuzumab for refractory minimal change disease in obese patients: a case series

  • By

  • Dandan Xue

  • Xiaofen Ma

  • Xiang Li

  • Yiming Zhang

  • Bing Xue

  • May 14, 2026

  • 0 min

Share

Top Institutions in Nephrology

Brief introduction explaining scope and methodology.

  • #1

    University of British Columbia
    University of British Columbia

    Vancouver, BC

    Key Differentiators

    • Nephrology

  • #2

    British Columbia Cancer Center Agency, Center for Lymphoid Cancer
    British Columbia Cancer Center Agency, Center for Lymphoid Cancer

    Vancouver, BC

    Key Differentiators

    • Oncology
    • Nephrology

  • #3

    Georgia Cancer Center
    Georgia Cancer Center

    Augusta, GA

    Key Differentiators

    • Oncology

  • #4

    Feinberg School of Medicine, Northwestern University
    Feinberg School of Medicine, Northwestern University

    Chicago, IL

    Key Differentiators

    • Medicine

  • #5

    Cleveland Clinic Taussig Cancer Institute
    Cleveland Clinic Taussig Cancer Institute

    Cleveland, OH

    Key Differentiators

    • Oncology

Original Source(s)

Obinutuzumab for refractory minimal change disease in obese patients: a case series

  • by Dandan Xue, Xiaofen Ma, Xiang Li, Yiming Zhang, Bing Xue

  • May 14, 2026

Related Content

Investigating Metabolic and Inflammatory Patterns in Staging Cardiovascular-Kidney-Metabolic Syndrome: A Comparative Cross-Sectional Analysis

Child Opportunity Index and Prevalence of Obesity and Hypertension in Adolescents with Congenital Heart Disease

The Ratio of Creatinine to Body Weight as a Predictor of Mortality in Critically Ill Heart Failure Patients: Insights from a Retrospective Analysis of the MIMIC-IV Database